2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes

Chiang, Chern‐En; Ueng, Kwo‐Chang; Chao, Ting‐Hsing; Lin, Tsung‐Hsien; Wu, Yih‐Jer; Wang, Kang-Ling; Sung, Shih‐Hsien; Yeh, Hung‐I; Li, Yi‐Heng; Liu, Ping-Yen; Chang, Kuan‐Cheng; Shyu, Kou‐Gi; Huang, Jin‐Long; Tsai, Cheng-Dao; Hung, Huei-Fong; Liu, Mingen; Chao, Tze‐Fan; Cheng, Shu‐Meng; Cheng, Hao‐Min; Chu, Pao‐Hsien; Yin, Wei‐Hsian; Wu, Yen-Wen; Chen, Wen‐Jone; Lai, Wen‐Ter; Lin, Shing‐Jong; Yeh, San-Jou; Hwang, Juey‐Jen; Hou, Charles Jia‐Yin

doi:10.1016/j.jacasi.2021.08.003

Cited by 2 publications

(1 citation statement)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Type 2 diabetes mellitus (T2DM), the most common type of chronic disease characterized by hyperglycemic metabolism, has become a public health problem, prevalence and incidence of which have been increasing in recent years (Katsiki et al, 2020;Zhou et al, 2021). T2DM may cause irreversible damage to the heart and blood vessels, kidneys, and eyes (Chiang et al, 2021). At present, sodiumglucose cotransporter 2 (SGLT2) inhibitors are novel therapeutic targets for the treatment of T2DM through inhibiting glucose reabsorption in renal proximal convoluted tubules, reducing blood glucose fluctuations, promoting urinary glucose excretion, improving insulin sensitivity and ß-cell function in the liver and peripheral tissues, and further improving hepatic insulin resistance (Li et al, 2020;Scheen, 2020).…”

Section: Introductionmentioning

confidence: 99%

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

et al. 2023

View full text Add to dashboard Cite

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have proven to be effective in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). However, the risk of diabetic ketoacidosis (DKA) in patients remains unclear. The purpose of this study is to conduct this systematic review and network meta-analysis for the risk of DKA of SGLT2 inhibitors in patients with T2DM.Methods: We searched for randomized controlled trials (RCTs) concerning SGLT2 inhibitors in patients with T2DM in PubMed, EMBASE (Ovid SP), Cochrane Central Register of Controlled Trials (Ovid SP), and ClinicalTrials.gov from inception to January 2022. The primary outcomes were the risk of DKA. We assessed the sparse network with a fixed-effect model and consistency model in a frequentist framework with a graph-theoretical method by the netmeta package in R. We assessed the evidence quality of evidence of outcomes according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE).Results: In total, 36 studies involving 52,264 patients were included. The network showed that there was no significant difference observed among SGLT2 inhibitors, other active antidiabetic drugs, and placebo in the risk of DKA. There was no significant difference in the DKA risk between different doses of SGLT2 inhibitors. The certainty of the evidence ranged from very low to moderate. The probabilities of rankings and P-score showed that compared to placebo, SGLT2 inhibitors might increase the risk of DKA (P-score = 0.5298). Canagliflozin might have a higher DKA risk than other SGLT2 inhibitors (P-score = 0.7388).Conclusion: Neither SGLT2 inhibitors nor other active antidiabetic drugs were associated with an increased risk of DKA compared to placebo, and the risk of DKA with SGLT2 inhibitors was not found to be dose-dependent. In addition, the use of canagliflozin was less advisable than other SGLT2 inhibitors according to the rankings and P-score.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier PROSPERO, CRD42021297081.

show abstract